Mechanism of Qili Qiangxin capsule in improving myocardial fibrosis:a study based on changes in gut microbiota metabolites
Chen Yun
Jiao Xueyan
Lan Zhenzhen
Zhang Ning
Zhang Yifan
Liu Luyao
Liu Shutong
Liu Xincan
Abstract：Objective To investigate the effects of Qili Qiangxin capsule on myocardial fibrosis in rats after myocardial infarction(MI)from the perspective of the changes in gut microbiota metab-olites trimethylamine N-oxide(TMAO)and lipopolysaccharide(LPS).Methods Sixty rats were randomly divided into sham operation group,model group,high-,medium-and low-dose Qili Qiangxin groups(1.0,0.5 and 0.25 g/kg),and perindopril group(0.84 mg/kg),with 10 rats in each group.Because 13 rats died during modeling,and 5 rats died during gavage,and finally,there were 8 rats in sham operation group,8 rats in model group,7,6 and 6 rats respectively in the high-,medium-and low-dose Qili Qiangxin groups,and 6 rats in perindopril group.Echocardio-graphy was used to detect the left ventricular ejection fraction(LVEF),left ventricular short axis shortening rate(FS),left ventricular end diastolic diameter(LVEDD)and left ventricular end systolic diameter(LVEDS).HE staining was used to observe the pathological morphology of my-ocardial and ileal tissues,and Masson staining was employed to detect myocardial fibrosis to cal-culate myocardial collagen volume fraction(CVF).The plasma content of TMAO was detected by liquid chromatography-mass spectrometry,and the contents of soluble growth stimulation expres-sion gene 2 protein(sST2)and LPS was determined by ELISA.Results Compared with the sham operation group,the model group had significantly decreased LVEF and FS,and increased LVEDD,LVEDS,sST2,TMAO,and LPS(P＜0.01).Compared with the model group,FS and LVEF in the high and medium-dose Qili Qiangxin groups and perindopril group were significantly increased(P＜0.01);the plasma sST2 content of the high-dose Qili Qiangxin group was signifi-cantly decreased(2025.45±413.13 pg/ml vs 2800.86±208.64 pg/ml,P＜0.01),the plasma TMAO content was significantly decreased(351.68±129.01 ng/ml vs 641.41±188.44 ng/ml,P＜0.01),and the plasma LPS content was significantly decreased(420.22±62.32 EU/L vs 594.62±83.4 EU/L,P＜0.05).Conclusion Qili Qiangxin capsule may improve myocardial fibro-sis by inhibiting the gut microbiota metabolites TMAO and LPS,and further research is needed to explore its mechanism.
Keywords：myocardial infarctionQi Li Qiang Xin Jiao Nangendomyocardial fibrosisgastrointes-tinal microbiomelipopolysaccharidestrimethylamine N-oxide
Publication Date：2024-04-15
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：5( 445-449 )